文献速递流行病学与生物统计临床试验与 GCP

稳定期慢性阻塞性肺疾病患者规律吸入治疗的急性加重与死亡率比较:系统评价与贝叶斯网络Meta分析

Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis.
PubMed 文献 · PLoS Med · 2019-11-15

该系统评价与贝叶斯网络Meta分析纳入219项随机对照试验共228,710例稳定期COPD患者,比较各类吸入药物对急性加重和死亡率的影响。结果显示ICS/LAMA/LABA在降低急性加重风险方面最有效,且与ICS/LABA一样较安慰剂显著降低死亡率,但ICS/LAMA/LABA增加肺炎概率。

要点

  • 与安慰剂相比,所有吸入药物类别均显著减少总急性加重和中重度急性加重。
  • ICS/LAMA/LABA降低急性加重风险最优(OR=0.57,95%CrI 0.50-0.64)。
  • ICS/LAMA/LABA和ICS/LABA较安慰剂显著降低死亡率,但ICS/LAMA/LABA增加肺炎概率(OR=1.56)。

核心结论

  • 研究结果提示,对于稳定期COPD患者,三联治疗可能成为降低急性加重和全因死亡率的最佳选择。

研究设计与样本

  • 系统评价与贝叶斯网络Meta分析,检索Medline、EMBASE、Cochrane对照试验中心注册库、ClinicalTrials.gov、欧盟临床试验注册库及制药公司官网(自建库至2019年7月9日)。
  • 纳入标准为平行设计随机对照试验、稳定期COPD成人、比较LAMA、LABA、ICS、联合治疗(ICS/LAMA/LABA、LAMA/LABA或ICS/LABA)或安慰剂、研究时长≥12周。
  • 共纳入219项试验,涉及228,710例患者;研究前瞻性注册于PROSPERO(CRD42017069087)。

主要发现

  • 与安慰剂相比,所有药物类别均显著减少总急性加重和中重度急性加重。
  • ICS/LAMA/LABA降低急性加重风险最有效(OR=0.57;95%CrI 0.50-0.64;P(OR>1)<0.001)。
  • ICS/LAMA/LABA较安慰剂显著降低死亡率(OR=0.74;95%CrI 0.59-0.93;P[OR>1]=0.004),ICS/LABA也显著降低死亡率(OR=0.86;95%CrI 0.76-0.98;P[OR>1]=0.015)。
  • ICS/LAMA/LABA有降低心血管死亡风险的趋势,但未显示显著结果。
  • ICS/LAMA/LABA增加肺炎概率(三联治疗OR=1.56;95%CrI 1.19-2.03;P[OR>1]=1.000)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要局限性是纳入的随机对照试验中仅包含症状较轻或低风险患者的研究很少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although exacerbation and mortality are the most important clinical outcomes of stable chronic obstructive pulmonary disease (COPD), the drug classes that are the most efficacious in reducing exacerbation and mortality among all possible inhaled drugs have not been determined. METHODS AND FINDINGS: We performed a systematic review (SR) and Bayesian network meta-analysis (NMA). We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, the European Union Clinical Trials Register, and the official websites of pharmaceutical companies (from inception to July 9, 2019). The eligibility criteria were as follows: (1) parallel-design randomized controlled trials (RCTs); (2) adults with stable COPD; (3) comparisons among long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICSs), combined treatment (ICS/LAMA/LABA, LAMA/LABA, or ICS/LABA), or a placebo; and (4) study duration ≥ 12 weeks. This study was prospectively registered in International Prospective Register of Systematic Reviews (PROSPERO; CRD42017069087). In total, 219 trials involving 228,710 patients were included. Compared with placebo, all drug classes significantly reduced the total exacerbations and moderate to severe exacerbations. ICS/LAMA/LABA was the most efficacious treatment for reducing the exacerbation risk (odds ratio [OR] = 0.57; 95% credible interval [CrI] 0.50-0.64; posterior probability of OR > 1 [P(OR > 1)] < 0.001). In addition, in contrast to the other drug classes, ICS/LAMA/LABA and ICS/LABA were associated with a significantly higher probability of reducing mortality than placebo (OR = 0.74, 95% CrI 0.59-0.93, P[OR > 1] = 0.004; and OR = 0.86, 95% CrI 0.76-0.98, P[OR > 1] = 0.015, respectively). The results minimally changed, even in various sensitivity and covariate-adjusted meta-regression analyses. ICS/LAMA/LABA tended to lower the risk of cardiovascular mortality but did not show significant results. ICS/LAMA/LABA increased the probability of pneumonia (OR for triple therapy = 1.56; 95% CrI 1.19-2.03; P[OR > 1] = 1.000). The main limitation is that there were few RCTs including only less symptomatic patients or patients at a low risk. CONCLUSIONS: These findings suggest that triple therapy can potentially be the best option for stable COPD patients in terms of reducing exacerbation and all-cause mortality.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Lee HW, Park J, Jo J, et al. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. PLoS Med. 2019. PMID: 31730642. doi:10.1371/journal.pmed.1002958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。